About this data
Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.
CKD-501
- Company
- Chong Kun Dang Pharmaceutical
- Mechanism
- Mechanism not yet reported
- Route
- Route not yet reported
- Recruiting trials
- None currently listed
Efficacy results: Not yet reported
No recruiting studies currently listed
See all studies for this drugData source: ClinicalTrials.gov · trial data as of Sep 11, 2026
Trial details
-
Completed NCT NCT01001611
An Evaluation of Glycemic Control Effects of Mono Therapy CKD-501 in Patients With Type 2 Diabetes Mellitus
Not yet reported Chong Kun Dang Pharmaceutical 173 participants Est. completion 2012-01 9 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT01005160
Drug Interaction Between CKD-501 and Metformin
Not yet reported Chong Kun Dang Pharmaceutical 24 participants Est. completion 2010-02 Stand-aloneOther conditions: Healthy Male VolunteersView official trial listing → -
Completed NCT NCT01030679
Evaluate the Glycemic Control of CKD-501 in Type 2 Diabetes Mellitus
Not yet reported Chong Kun Dang Pharmaceutical 214 participants Est. completion 2008-10 8 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT01071720
The Effect of Food on the Pharmacokinetic Characteristics of CKD-501
Not yet reported Chong Kun Dang Pharmaceutical 24 participants Est. completion 2010-08Other conditions: HealthyView official trial listing → -
Completed NCT NCT01106131
Efficacy and Safety of CKD-501 Versus Pioglitazone When Added to Metformin
Not yet reported Chong Kun Dang Pharmaceutical 253 participants Est. completion 2012-11 1 site Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT01133431
The Pharmacokinetic Interaction Between CKD-501 and Sulfonylurea
Not yet reported Chong Kun Dang Pharmaceutical 24 participants Est. completion 2010-08 1 site Stand-aloneOther conditions: Healthy Male VolunteerView official trial listing → -
Completed NCT NCT01330563
Drug-drug Interaction Study (CKD-501, Ketoconazole)
Not yet reported Chong Kun Dang Pharmaceutical 24 participants Est. completion 2011-06 1 site Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT01341392
Drug-drug Interaction Study(CKD-501, Amlodipine)
Not yet reported Chong Kun Dang Pharmaceutical 25 participants Est. completion 2011-08 1 site Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT02002611
Drug-drug Interaction Study(Lobeglitazone, Warfarin)
Not yet reported Chong Kun Dang Pharmaceutical 24 participants Est. completion 2014-05 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT02005744
A Pharmacokinetic Study of CKD-501 in Patients With Impaired Hepatic Function
Not yet reported Chong Kun Dang Pharmaceutical 26 participants Est. completion 2016-02 1 site Stand-aloneOther conditions: Liver DysfunctionView official trial listing → -
Completed NCT NCT02007941
Comparative Evaluation of Pharmacokinetics After CKD-501 Between Renal Impaired and Normal Renal Function Subjects
Not yet reported Chong Kun Dang Pharmaceutical 28 participants Est. completion 2015-04 1 site Stand-aloneOther conditions: Renal Impairment, HealthyView official trial listing → -
Completed NCT NCT02188186
Therapeutic Efficacy of Triple Combination in Drug-naïve Korean Type 2 Diabetic Patients
Not yet reported Seoul National University Bundang Hospital 200 participants Est. completion 2018-09 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT02285205
A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD
Not yet reported Yonsei University 38 participants Est. completion 2015-11 1 siteType 2 diabetes Other conditions: Non-alcoholic Fatty Liver DiseaseView official trial listing → -
Status unknown NCT NCT02315287
Comparison of Lobeglitazone With Pioglitazone as Initial Triple Therapy for Diabetes Management
Not yet reported Seoul National University Bundang Hospital 190 participants Est. completion 2021-12-31 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT02338921
Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination Therapy
Not yet reported Seoul National University Bundang Hospital 78 participants Est. completion 2021-12-31 1 siteType 2 diabetesView official trial listing → -
Status unknown NCT NCT02480465
Efficacy and Safety of Lobeglitazone Versus Sitagliptin
Not yet reported Chong Kun Dang Pharmaceutical 248 participants Est. completion 2017-03 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT02565368
A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.5/1000 mg in Healthy Male Volunteers
Not yet reported Chong Kun Dang Pharmaceutical 26 participants Est. completion 2015-08 1 siteOther conditions: Diabetes Mellitus, Type IIView official trial listing → -
Completed NCT NCT02627027
A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.25/750 mg in Healthy Male Volunteers
Not yet reported Chong Kun Dang Pharmaceutical 26 participants Est. completion 2015-09 1 siteOther conditions: Diabetes Mellitus, Type IIView official trial listing → -
Completed NCT NCT02648854
Investigate the Effect of Food on the Pharmacokinetic Characteristics of CKD-395 in Healthy Male Volunteers
Not yet reported Chong Kun Dang Pharmaceutical 26 participants Est. completion 2015-11 1 siteOther conditions: Diabetes Mellitus, Type IIView official trial listing → -
Completed NCT NCT02824874
CKD-396 Drug-drug Interaction Study(A) (CKD-396 DDI(A) P1)
Not yet reported Chong Kun Dang Pharmaceutical 20 participants Est. completion 2016-05 1 siteOther conditions: Diabetes Mellitus, Type IIView official trial listing → -
Completed NCT NCT02827890
CKD-396 Drug-drug Interaction Study(B) (CKD-396 DDI(B) P1)
Not yet reported Chong Kun Dang Pharmaceutical 20 participants Est. completion 2016-05 1 siteType 2 diabetesView official trial listing → -
Status unknown NCT NCT02854748
Evaluate the Drug-drugs Interaction Between Lobeglitazone and Empagliflozin
Not yet reported Chong Kun Dang Pharmaceutical 30 participants Est. completion 2016-09 1 siteOther conditions: Diabetes Mellitus, Type IIView official trial listing → -
Completed NCT NCT03616392
Clinical Trial to Evaluate the Drug Drug Interaction of CKD-501 and D308
Not yet reported Chong Kun Dang Pharmaceutical 41 participants Est. completion 2018-11-13 1 site Stand-aloneOther conditions: Diabetes Mellitus, Type IIView official trial listing → -
Status unknown NCT NCT03627182
Efficacy and Safety of CKD-501 Added to D150 Plus D745 25mg Therapy in Patients With Type 2 Diabetes
Not yet reported Chong Kun Dang Pharmaceutical 240 participants Est. completion 2023-02-10 1 site Stand-aloneType 2 diabetesView official trial listing → -
Status unknown NCT NCT03641352
The Efficacy and Safety of CKD-501 Added to D150 Plus D759 Therapy in Patients With Type 2 Diabetes
Not yet reported Chong Kun Dang Pharmaceutical 240 participants Est. completion 2022-11-30 1 site Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT03739125
Efficacy and Safety of CKD-501 Added to D150 Plus D745 10mg Therapy in Patients With Type 2 Diabetes
Not yet reported Chong Kun Dang Pharmaceutical 226 participants Est. completion 2020-12-02 1 site Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT03770052
Glucose-Lowering Effects and Safety of Adding 0.25 or 0.5 mg Duvie
Not yet reported Pusan National University Hospital 159 participants Est. completion 2021-09-13 1 siteType 2 diabetes Other conditions: Inadequate Glucose ControlView official trial listing → -
Status unknown NCT NCT04246190
A Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-396
Not yet reported Chong Kun Dang Pharmaceutical 26 participants Est. completion 2020-07-16 1 site Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT04260438
Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-393 in Healthy Subjects
Not yet reported Chong Kun Dang Pharmaceutical 24 participants Est. completion 2020-06-24 1 site Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT04334213
A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction and Safety of CKD-501, D745 and D150
Not yet reported Chong Kun Dang Pharmaceutical 48 participants Est. completion 2020-08-05 1 site Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT04431687
A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction and Safety of CKD-501, D759 and D150 (CKD-393)
Not yet reported Chong Kun Dang Pharmaceutical 48 participants Est. completion 2020-10-26 1 site Stand-aloneType 2 diabetesView official trial listing → -
Status unknown NCT NCT04706286
Clinical Trial to Investigate the Pharmacokinetics and Safety of CKD-393
Not yet reported Chong Kun Dang Pharmaceutical 26 participants Est. completion 2021-04-05 1 site Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT04768673
A Study to Investigate the PK and Safety of CKD-393
Not yet reported Chong Kun Dang Pharmaceutical 26 participants Est. completion 2021-04-27 1 site Stand-aloneOther conditions: Type II DiabetesView official trial listing → -
Completed NCT NCT04810676
A Clinical Trial to Evaluate the Pharmacokinetic Profiles and Safety of CKD-383.
Not yet reported Chong Kun Dang Pharmaceutical 27 participants Est. completion 2021-05-26 1 site Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT04869800
Evaluate the Drug-drugs Interaction Between Lobeglitazone 0.5mg and Empagliflozin 25mg
Not yet reported Chong Kun Dang Pharmaceutical 32 participants Est. completion 2021-06-15 1 site Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT05043467
Retrospective Study to Evaluate the Safety of Duvie in Korean Patients With Type 2 Diabetes Mellitus
Chong Kun Dang Pharmaceutical 2228 participants Est. completion 2020-06-19 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT05113693
Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393
Not yet reported Chong Kun Dang Pharmaceutical 33 participants Est. completion 2021-12-10 1 site Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT05347576
A Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393(2) in Healthy Volunteers Under Fed Conditions
Not yet reported Chong Kun Dang Pharmaceutical 31 participants Est. completion 2022-05-09 1 site Stand-aloneOther conditions: Type2DiabetesView official trial listing → -
Completed NCT NCT05816759
Evaluate the Pharmacokinetics and Safety Between the Administration of CKD-383 and the Co-administration of CKD-501, D744, and D150
Not yet reported Chong Kun Dang Pharmaceutical 32 participants Est. completion 2023-06-22 1 site Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT05897216
Evaluate the Pharmacokinetics and Safety Between the Treatment of CKD-383 and Treatment of CKD-501, D745, D150, and D029
Not yet reported Chong Kun Dang Pharmaceutical 30 participants Est. completion 2023-08-08 1 site Stand-aloneType 2 diabetesView official trial listing → -
Status unknown NCT NCT05915949
Comparison of Dapagliflozin, Lobeglitazone, and Its Combination in Efficacy and Safety
Not yet reported Seoul National University Bundang Hospital 99 participants Est. completion 2023-12-31 1 siteOther conditions: Diabetes Type 2View official trial listing → -
Completed NCT NCT06483243
Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic of CKD-501, D745, and D150 for Healthy Subjects in Fed State.
Not yet reported Chong Kun Dang Pharmaceutical 45 participants Est. completion 2024-05-17 1 site Stand-aloneType 2 diabetesView official trial listing → -
Status unknown NCT NCT06492655
To Evaluate the Food Effect on Pharmacokinetic Profiles and Safety in Healthy Volunteers
Not yet reported Chong Kun Dang Pharmaceutical 28 participants Est. completion 2024-08-08Type 2 diabetesView official trial listing → -
Completed NCT NCT07056517
Pharmacokinetics and Safety of M107 Orally Disintegrating Tablet in Healthy Adults
Not yet reported Aclipse Two Inc. 21 participants Est. completion 2025-09-22 1 siteOther conditions: HealthyView official trial listing → -
Not yet recruiting NCT NCT07108985
Effect of Add-on SGLT2i, TZD, or Combination Therapy in Type 2 Diabetes Patients on DPP4 Inhibitors
Not yet reported Yonsei University 100 participants Est. completion 2030-08-31 1 siteType 2 diabetes Other conditions: Hyperglycemia, Insulin ResistanceView official trial listing → -
Completed NCT NCT07304687
Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/25/1000mg in Healthy Volunteers
Not yet reported Chong Kun Dang Pharmaceutical 31 participants Est. completion 2025-11-22 1 site Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT07304700
Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/10/1000mg in Healthy Volunteers
Not yet reported Chong Kun Dang Pharmaceutical 30 participants Est. completion 2025-11-12 1 site Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT07304726
Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.25/12.5/1000mg in Healthy Volunteers
Not yet reported Chong Kun Dang Pharmaceutical 30 participants Est. completion 2025-11-23 1 site Stand-aloneType 2 diabetesView official trial listing →
Efficacy history
Not yet reported.
Safety
Not yet reported.
Sources
Related On The Pen coverage
No related coverage yet.
This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.